STAT3 inhibitor, cucurbitacin I, is a novel therapeutic agent for osteosarcoma

The development of clinical agents remains a costly and time-consuming process. Although identification of new uses of existing drugs has been recognized as a more efficient approach for drug discovery than development of novel drugs, little screening of drugs that might be used for a rare malignant...

Descripción completa

Detalles Bibliográficos
Autores principales: Oi, Toru, Asanuma, Kunihiro, Matsumine, Akihiko, Matsubara, Takao, Nakamura, Tomoki, Iino, Takahiro, Asanuma, Yumiko, Goto, Mikinobu, Okuno, Kazuma, Kakimoto, Takuya, Yada, Yuki, Sudo, Akihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117998/
https://www.ncbi.nlm.nih.gov/pubmed/27840900
http://dx.doi.org/10.3892/ijo.2016.3757

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117998/
https://www.ncbi.nlm.nih.gov/pubmed/27840900
http://dx.doi.org/10.3892/ijo.2016.3757

Ejemplares similares